MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2017 International Congress

    Motor and Body Composition Variables by Parkinson’s Disease Staging

    L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

    Objective: Knowing the motor variables involved in the relationship of body composition and staging of disease. Background: Functional limitation, defined as a restriction in the…
  • 2017 International Congress

    Neuroprotective propensity of PTUPB, a dual inhibitor of sEH and COX-2 against rotenone induced neurotoxicity in cell line and Drosophila model of Parkinson disease

    N. Lakkappa, P. Thaggikuppe Krishnamurthy, P.D. Mirazkar, N. Lakkappa, P. Krishnamurthy, P.M.D., M.M. Srinivas Bharath, B. Hammock, S.H. Hwang (Udhagamandalam, India)

    Objective: To evaluate the potential anti-parkinson activity of PTUPB (4-(5-phenyl-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide) a dual inhibitor of soluble Epoxide hydrolase (sEH) and cyclooxygenase-2 (COX-2) against rotenone induced mitochondrial dysfunction,…
  • 2017 International Congress

    Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, M. Hebron, Y. Torres-Yaghi, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, A. Shekoyan, J. Ahn, C. Moussa (Washington, DC, USA)

    Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…
  • 2017 International Congress

    Deep Learning in Objective Classification of Spontaneous Movement of Patients with Parkinson’s Disease Using Large-Scale Free-Living Sensor Data

    F. Pfister, D. Kulić, T. Um, D. Pichler, A. Ahmadi, M. Lang, G. König, F. Achilles, S. Endo, K. Abedinpour, K. Ziegler, K. Bötzel, S. Hirche, A. Ceballos-Baumann, U. Fietzek (Munich, Germany)

    Objective: Our goal was to classify spontaneous movement using a commercially available motion sensor in a clinically meaningful 3-/9-step discrete scale (SMS-3/SMS-9). Background: Brady-hypokinetic and dyskinetic…
  • 2017 International Congress

    Tandem Standing

    E. Okuyucu, E. Dogru Huzmeli, S. Colakoglu Yesildag, I. Huzmeli (Hatay, Turkey)

    Objective: The aim of this study is to learn, patients who can’t make tandem standing fall more or not? Background: Falls occur more often with…
  • 2017 International Congress

    A Preliminary Study: Validity and Reliability of Parkinson Fatigue Scale (PFS) in Turkish Patients with Parkinson’s Disease (PD)

    E. Ozturk, E. Ozturk, B. Gonenli Kocer, I. Gundogdu, A. Cakci, E. Umay (Ankara, Turkey)

    Objective: The purpose of this study was to investigate the validity and reliability of the Turkish version of PFS. Background: The PFS is a 16-item…
  • 2017 International Congress

    Functional Connectivity Differences Across Parkinson Disease Subtypes

    M. Campbell, C. Gratton, J. Koller, W. Shannon, C. Lessov-Schlaggar, S. Petersen, J. Perlmutter (St. Louis, MO, USA)

    Objective: The goals of this project were to 1) identify putative Parkinson disease (PD) clinical subtypes and 2) investigate resting-state functional connectivity differences between these…
  • 2017 International Congress

    Multicenter Validation of Disease- related Parkinson’s disease pattern with Resting State functional MRI

    K. Schindlbeck, A. Vo, Y. Ma, S. Peng, K. Poston, H. Hurtig, N. Dahodwala, D. Eidelberg (Manhasset, NY, USA)

    Objective: To validate Parkinson’s Disease-related network topography characterized with resting-state functional MRI (rs-fMRI) in two multicenter based cohorts of idiopathic Parkinson’s disease (IPD) patients.  Background:…
  • 2017 International Congress

    Olfactory Impairment in Parkinson’s Disease and White Matter Abnormalities in Central Olfactory Areas

    S. Sobhani, M. Aarabi (Tehran, Islamic Republic of Iran)

    Objective: To determine white matter abnormalities in PD patients with various degrees of olfactory impairment. Background: Neuroimaging results of PD brain based on diffusion tensor…
  • 2017 International Congress

    Analysis of related factors of occurrence of dementia in Parkinson’s disease using the application form of Parkinson’s disease provided by the specific diseases treatment research program of Ministry of Health, Labor and Welfare of Japan

    K. Konaka, M. Mihara, H. Mochizuki (Suita, Japan)

    Objective: Dementia has now been noticed as a significant non-motor symptom of Parkinson's disease (PD). We attempted to analyze the relation between the occurrence of…
  • « Previous Page
  • 1
  • …
  • 302
  • 303
  • 304
  • 305
  • 306
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley